10-Year Experience in Performing Saturation Prostate Biopsy*
Publicado
Mar 6, 2019
Almetrics
Dimensions
Google Scholar
##plugins.themes.bootstrap3.article.details##
Resumo
Objective: Identify the prostate cancer detection rate in patients in whom underwent a saturation prostate biopsy as a rebiopsy from January 2005 to February 2015 at San Ignacio Hospital. Materials and methods: In San Ignacio hospital were performed from January 2005 to February 2015, 114 saturation biopsies. The investigators made a univariate analysis of the variables. The association between the variable was evaluated based on the T-test and Wilcoxon test. P < 0.05 was considered statistically significant. Finally, a regression model was performed to predict significant variables for prostate cancer. Results: The cancer detection rate using saturation prostate biopsy was 16.7% of which 84% were categorized as significant. A mean of 19 cores were obtained. There were statistically significant differences between patients with prostate cancer and healthy patients in the number of previous biopsies, number of samples, prostate volume and PSA density. Conclusion: Saturation prostate biopsy in our study has a prostate cancer detection rate of 16.7% and 84% of them were significant in this cohort of patients.
Keywords
References
1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195-200. Epub 2012/04/06.
2. Instituto Nacional de Cancerología. Información sobre el cancer [internet]. Instituto Nacional de Cancerologia; 2011 [updated 2011; cited 2014 ene 4]. Disponible en: http://www.cancer.gov.co/contenido/contenido.aspx?catID=434&conID=790.
3. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142(1):71-4; discussion 4-5. Epub 1989/07/01.
4. Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, et al. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol. 2013;63(2):214-30. Epub 2012/10/02.
5. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol. 2000;164(2):388-92. Epub 2000/07/14.
6. Siu W, Dunn RL, Shah RB, Wei JT. Use of extended pattern technique for initial prostate biopsy. J Urol. 2005;174(2):505-9. Epub 2005/07/12.
7. Scattoni V, Maccagnano C, Zanni G, Angiolilli D, Raber M, Roscigno M, et al. Is extended and saturation biopsy necessary? Int J Urol.. 2010;17(5):432-47. Epub 2010/04/27.
8. Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Sacca A, et al. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int. 2012;89(2):126-35. Epub 2012/07/21.
9. Instituto Nacional de Cancerología, Sociedad Colombiana de Urología. Guía de práctica clínica (GPC) para la detección temprana, diagnóstico, tratamiento integral, seguimiento y rehabilitación de pacientes con diagnóstico de cáncer de próstata para el Sistema General de Seguridad Social en Salud, Colombia [internet]. Bogotá: Ministerio de Salud y Protección Social-Departamento Administrativo de Ciencia Tecnología e Innovación en Salud (Colciencias); 2013. Disponible en: https://docs.supersalud.gov.co/PortalWeb/Comunicaciones/GuiasPracticasClinica/guia015-2013-cancer-de-prostata-01-08-13.pdf
10. Centers for Disease Control and Prevention. Cancer among men [internet]; 2013 [citado 2014 ene 4]. Disponible en: http://www.cdc.gov/cancer/dcpc/data/men.htm.
11. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014;12(9):1211-9; quiz 9. Epub 2014/09/06.
12. Mottet N, Bastian P, Bellmunt J, van den Bergh R, Bolla M, van Casteren N, et al. Guidelines on prostate cancer. Eur Urol. 2014;65(1):124-37.
13. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(1 Suppl):S2-S11. Epub 2012/12/19.
14. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2001;166(5):1679-83. Epub 2001/10/05.
15. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167(6):2435-9. Epub 2002/05/07.
16. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166(1):86-91; discussion -2. Epub 2001/07/04.
17. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-74. Epub 1994/02/02.
18. Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol. 2011;186(3):850-4. Epub 2011/07/27.
19. Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB, et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol. 2014;192(3):648-58. Epub 2014/04/29.
20. Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012;62(5):902-9. Epub 2012/02/14.
21. Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. Radiology. 2011;259(1):162-72. Epub 2011/01/15.
22. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res.. 2010;16(6):1875-83. Epub 2010/03/04.
23. Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol. 2006;50(4):738-48; discussion 48-9. Epub 2006/04/25.
2. Instituto Nacional de Cancerología. Información sobre el cancer [internet]. Instituto Nacional de Cancerologia; 2011 [updated 2011; cited 2014 ene 4]. Disponible en: http://www.cancer.gov.co/contenido/contenido.aspx?catID=434&conID=790.
3. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142(1):71-4; discussion 4-5. Epub 1989/07/01.
4. Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, et al. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol. 2013;63(2):214-30. Epub 2012/10/02.
5. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol. 2000;164(2):388-92. Epub 2000/07/14.
6. Siu W, Dunn RL, Shah RB, Wei JT. Use of extended pattern technique for initial prostate biopsy. J Urol. 2005;174(2):505-9. Epub 2005/07/12.
7. Scattoni V, Maccagnano C, Zanni G, Angiolilli D, Raber M, Roscigno M, et al. Is extended and saturation biopsy necessary? Int J Urol.. 2010;17(5):432-47. Epub 2010/04/27.
8. Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Sacca A, et al. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int. 2012;89(2):126-35. Epub 2012/07/21.
9. Instituto Nacional de Cancerología, Sociedad Colombiana de Urología. Guía de práctica clínica (GPC) para la detección temprana, diagnóstico, tratamiento integral, seguimiento y rehabilitación de pacientes con diagnóstico de cáncer de próstata para el Sistema General de Seguridad Social en Salud, Colombia [internet]. Bogotá: Ministerio de Salud y Protección Social-Departamento Administrativo de Ciencia Tecnología e Innovación en Salud (Colciencias); 2013. Disponible en: https://docs.supersalud.gov.co/PortalWeb/Comunicaciones/GuiasPracticasClinica/guia015-2013-cancer-de-prostata-01-08-13.pdf
10. Centers for Disease Control and Prevention. Cancer among men [internet]; 2013 [citado 2014 ene 4]. Disponible en: http://www.cdc.gov/cancer/dcpc/data/men.htm.
11. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014;12(9):1211-9; quiz 9. Epub 2014/09/06.
12. Mottet N, Bastian P, Bellmunt J, van den Bergh R, Bolla M, van Casteren N, et al. Guidelines on prostate cancer. Eur Urol. 2014;65(1):124-37.
13. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(1 Suppl):S2-S11. Epub 2012/12/19.
14. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2001;166(5):1679-83. Epub 2001/10/05.
15. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167(6):2435-9. Epub 2002/05/07.
16. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166(1):86-91; discussion -2. Epub 2001/07/04.
17. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-74. Epub 1994/02/02.
18. Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol. 2011;186(3):850-4. Epub 2011/07/27.
19. Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB, et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol. 2014;192(3):648-58. Epub 2014/04/29.
20. Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012;62(5):902-9. Epub 2012/02/14.
21. Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. Radiology. 2011;259(1):162-72. Epub 2011/01/15.
22. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res.. 2010;16(6):1875-83. Epub 2010/03/04.
23. Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol. 2006;50(4):738-48; discussion 48-9. Epub 2006/04/25.
Como Citar
Villarraga, L. G., Ramos, J. G., De La Hoz, J., & Cataño Cataño, J. G. (2019). 10-Year Experience in Performing Saturation Prostate Biopsy*. Universitas Medica, 57(4), 430–437. https://doi.org/10.11144/Javeriana.umed57-4.year
Edição
Seção
Artículos originales